Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Maxilac
- Development stage
- Unknown
- Lead developer
- Binnopharm
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Maxilac is a synbiotic dietary supplement containing a combination of nine probiotic bacterial strains and a prebiotic component (oligofructose). It is designed to support and restore healthy intestinal microflora, particularly during or after antibiotic therapy, and to manage functional bowel disorders such as diarrhea, dyspepsia, constipation, flatulence, and abdominal pain. The product is owned and marketed by Binnopharm Group in Russia and the CIS, and is manufactured by European partners including Danisco, Labomar, Genexo, and Havea Industrie. Maxilac utilizes specialized protective technologies such as SFERA (Surrounded Freeze Release Armour) and MURE (Multi Resistant Encapsulation) to protect the probiotic strains from gastric acid and digestive enzymes, ensuring delivery of viable bacteria directly to the intestines.
- Brand names
- MaxilacMaxilac BabyМаксилакМаксилак Бэби
Beyond the preview
Go deeper on Maxilac.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Maxilac.